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Over the past decade, screening and identifying novel compounds for their biomedical
applications has become an upcoming area of research. Identifying the molecular
mechanisms of these compounds has become an integral part of anticancer research.
β-elemene, a sesquiterpene, is renowned for its anticancer activity against a variety
of cell lines. Recent studies on β-elemene have elucidated that it possesses anti-
proliferative effect on cancer cells by creating an apoptotic trigger. Interestingly, it
also induces protective autophagy in some cancerous cell lines and is less cytotoxic
compared to other widely accepted chemotherapeutic agents. This provides an edge
with the perception of limited toxicity to normal cells. This mini-review precisely focuses
on the studies performed to identify the mechanism of anticancer activity of β-elemene
against cancer cells of multiple origin. In accordance to the evaluation made by the
studies mentioned, apoptosis has been identified to be most possible reason behind
anticancer activity exerted by β-elemene against a variety of cancer cell lines. Cell cycle
arrest and necrosis have been credited to be possible alternate mechanisms for the
anticancer effect of β-elemene.
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INTRODUCTION
Cancer is the reason behind highest number of deaths across the world and contemporary measures
have become the need of the hour (Siegel et al., 2016). β-elemene is a sesquiterpene, with a
wide spectrum of antineoplastic activity, even against drug-resistant tumors and other complex
malignancies (Liu et al., 2011). Among its three isomers (δ, α, β), β-elemene (referred to as elemene,
hereafter), is the predominant component (Wu et al., 2009).
The most well studied mechanism by which anticancer agents induce cell death in cancer
cells is by the induction of apoptosis (Frankfurt and Krishan, 2003). DNA fragmentation and
activation of caspases are the major hallmarks of apoptosis (Saraste and Pulkki, 2000). Apoptosis
has been strongly induced in cancerous cells by elemene (Guan et al., 2014). Elemene, a prominent
component of traditional chinese medicine (TCM) regulates several molecular targets and exerts
promising anticancer effects (Jiang et al., 2016). Although elemene can induce antitumor effects in
cancerous cells of multiple origin, the mechanism of action still remains unclear (Zhu et al., 2011b).
In the current mini-review, the mechanism of action of elemene was reviewed and analyzed.
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ELEMENE MECHANISM OF ACTION
AGAINST CANCER CELLS OF MULTIPLE
ORIGIN
Integumentary System
In B16F10 melanoma cells, the expression of VEGF was
inhibited by elemene elucidating its antiangiogenic activity.
Similar results were obtained in rat aortic ring and chicken
embryo chorioallantoic membrane. In C57BL/6 melanoma mice,
western blot and immunohistochemical analysis showed that
CD34 expression was reduced, further evidenced by reduction in
tumor volume and suppression of VEGF-mediated angiogenesis.
This study therefore determines that the antineoplastic effect of
elemene in cells of melanoma origin is by an antiangiogenic effect
(Chen et al., 2011).
Nervous System
Mitogen-activated protein kinase kinase-3 (MKK3) and -6
(MKK6), is a kinase enzyme which phosphorylates
mitogen-activated protein kinase (MAPK). When activated
through mutual compensation, it can mediate the
antiglioblastoma effect of elemene. In the human U87
glioblastoma cell line, the upregulation of MKK3 and MKK6 can
lead to cell cycle arrest at the G0/G1 phase thereby leading to an
anticancer effect of elemene (Zhu et al., 2011b). Elemene, in a
similar study, inhibited the proliferation of U87 cells through the
Glia maturation factor β -dependent inactivation of the ERK1/2-
Bcl-2/survivin pathway. It also chemosensitized the glioblastoma
cells to temozolomide (Zhu et al., 2014). In C6 and U251
glioblastoma cells, elemene treatment resulted in p38 MAPK
phosphorylation and cell-cycle arrest at the G0/G1 phase (Yao
et al., 2008a,b). Activation of Glia maturation factor β mediates
the antitumor effect of elemene in glioblastoma cell line U87 and
this can increase the sensitivity of cancer cells to cisplatin (Zhu
et al., 2011a). Therefore, the antiglioblastoma effect of elemene
is mediated through the cell cycle arrest at G0/G1 phase, leading
to MAPK phosphorylation. The p38 MAPK phosphorylation is
activated by the upregulation of MKK3 and MKK6 (Son et al.,
2010). The activation of p38 MAPK eventually leads to cellular
apoptosis (Koul et al., 2013). Therefore, these studies are an
evidence for killing of glioblastoma cells by elemene via an
apoptotic trigger.
Supporting this view, elemene increased caspase-3/7/10
activity, up-regulated Bax expression, and down-regulated the
Bcl-2, Bcl-XL, and of X-linked inhibitor of apoptosis expressions.
This suggests the role of apoptosis in anticancer effect of elemene
on brain tumor cell lines A172, CCF-STTG1, and U-87MG (Li
et al., 2013b). Elemene induced cell cycle arrest at G0/G1 phase
in U87 cells and elevated the expressions of caspases-3, -8, -9,
Fas, FasL, and Bax. It downregulated the expressions of Bcl-2,
indicating the induction of apoptosis in the cancer cells (Li et al.,
2014). In glioma U251 and A172 cells, elemene induced apoptosis
through upregulation of caspase-9, -3 and -7 expressions and
downregulation of survivin gene expression (Zhang et al., 2012).
Against the rat glioma cell C6 and human glioma cell SHG-44,
elemene possessed antiproliferative effects through induction
of apoptosis (Zhou et al., 2003). These studies prove that the
antineoplastic effect of elemene against cancers of nervous system
is by the induction of apoptosis.
Respiratory System
In the human NSCLC cell lines H460 and A549, a Chk2-
dependent mechanism adopted by elemene caused the G2-
M arrest. Elemene induced caspase-3, -7, and -9 activities,
decreased Bcl-2 expression, resulted in cytochrome c release
and increased the levels of cleaved caspase-9 and poly (ADP-
ribose) polymerase through a mitochondrial release of the
cytochrome c-mediated apoptotic pathway (Wang et al., 2005).
Elemene and etoposide phosphate in synergism can induce
the expressions of Bax, p53, and p21, mediated by cleavage
of PARP and the suppression of cyclin D1 in A549 NSCLC
cells (Zhang et al., 2011). Elemene can restore the sensitivity
of NSCLC cells (PC9 and H1299) to Gefitinib by upregulation
of p21 expression (Zhao et al., 2011). p21 is a key arbitrator
of p53 function, which can lead to apoptosis (Xia et al., 2011).
Elemene can induce the expressions of Bax and phospho-
Bcl-2 and decrease Bcl-2 and XIAP expressions in human
NSCLC cell lines H460 and A549. It can also increase the
cisplatin-induced expressions of caspase-3, -7, -9, and -10
activities and cleaved caspase-3, -9, and poly (ADP-ribose)
polymerase levels thereby sensitizing the cells to cisplatin by
mitochondria-mediated intrinsic apoptosis pathway (Li et al.,
2009). Elemene has antiproliferative effects on human NSCLC
PC9, H1299, H1650, A549, H358, and H1975 cells by ERK1/2-
and AMPKα-mediated inhibition of transcription factor Sp1,
followed by reduction in DNMT1 protein expression (Zhao et al.,
2015).
Elemene in synergism with Docetaxel resulted in increased
cytochrome c release from mitochondria, significant caspase-
8 and -3 cleavage, and downregulation of Bcl-2 and Bcl-
XL expressions in p53 mutant H23 cells and p53 null H358
cells thereby leading to a p53- and Fas-independent pathway
via mitochondria (Zhao et al., 2007). In laryngeal HEp-2
cells, in vitro and HEp-2 cell-transplanted BALB/c nude mice,
in vivo, elemene enhanced the expression of caspase-3, thereby
inhibiting the eukaryotic initiation factors (eIF4E and eIF4G),
basic fibroblast growth factor (bFGF), and vascular endothelial
growth factor (VEGF) (Tao et al., 2006). Collectively, the
results of these studies elucidate that the antineoplastic effect of
elemene in cancers of respiratory system is by the induction of
apoptosis.
Immune System
Five piperazine derivatives of β-elemene were synthesized and
their antileukemic effect was tested against HL-60, NB4, K562m
and HP100-1. DX-1 was effective in induction of apoptosis in
HL-60 cell line by both receptor and mitochondria mediated
pathways. Caspase-8 activation was correlated with the decrease
in the levels of cellular FLICE-inhibitory protein (c-FLIP),
an inhibitor of apoptosis triggered by engagement of death
receptors (Yu et al., 2011). When treated against HL-60 cells,
elemene enhanced the apoptotic effect induced by aclarubicin
and down-regulated COX-2, NF-kappaB and PGE2 expressions
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(Zheng et al., 2009). When elemene was treated against human
multiple myeloma cell line RPMI-8226, caspase-3, and DR-
4 protein expressions increased, whereas, bcl-2, NF-kappaB
and P65 protein expressions decreased. Apoptosis induced by
elemene may be by activation of mitochondrial and death
receptor mediated pathways, according to the authors (Chen
et al., 2010).
An elemene derivative named N-(beta-elemene-13-yl)
tryptophan, treated against human acute promyelocytic
leukemia NB4 cells resulted in apoptotic cell death mediated
by hydrogen peroxide generation and activation of caspase-3
(Yu, 2010). Taken together, elemene exerts its antineoplastic
on cancers of immune system through induction of
apoptosis.
Digestive System
The copper transporter 1 levels are increased by treatment
with elemene, which can allow the entry of oxaliplatin into
hepatocellular carcinoma cell lines MHCC97H and Hep3B. This
will result in increased sensitivity of cancer cells to oxaliplatin
(Li et al., 2016). Against the hepatoma cell line HepG2, elemene
can induce cell cycle arrest at G2/M phase and cell death by
apoptosis by upregulating Fas/FasL expression (Dai et al., 2013).
Multidrug resistant variant human gastric adenocarcinoma
SGC7901/ADM cell line was treated with elemene. Apoptosis
was observed with increasing concentrations of elemene and
it also increased the sensitivity of the cell line to adriamycin
which might be due to inhibition of NF-kappaB activity (Fu
et al., 2013). Elemene suppressed the proliferation of esophageal
carcinoma ECA-109 cells by inhibiting the human telomerase
reverse transcriptase expression using a long noncoding RNA
CDKN2B-AS1 (Hu et al., 2015). These results also stand
supportive for the antineoplastic effect of elemene through an
apoptotic trigger.
Reproductive System
Elemene inhibited the proliferation of androgen-insensitive
prostate carcinoma DU145 and PC-3 cells and induced apoptosis
as observed by TUNEL assay and flow cytometric analysis. This
was further evidenced by decreased levels of bcl-2, increased
levels of cytochrome c release, activated PARP and caspase-3,
-7, -9, and -10 in prostate cancer cells after elemene treatment
(Li et al., 2010a). In a similar study, elemene treatment
against the androgen-independent prostate carcinoma DU145
and PC-3 cells resulted in mitochondria mediated apoptosis.
Elemene acted as a chemosensitizing agent for cisplatin in
this study by augmenting the cisplatin-induced activation
of caspases-3, 7, 9, and 10, cleavage of caspase-3 and -9,
suppression of Bcl-2 and Bcl-XL expression, and release of
cytochrome c from the mitochondria of these cells (Li et al.,
2010b).
In the cisplatin-sensitive human ovarian cancer cell line A2780
and its cisplatin-resistant counterpart A2780/CP, treatment of
elemene alone or in synergism with cisplatin, resulted in
alterations in cyclin and cyclin-dependent kinase expression,
including the down-regulation of CDC2, cyclin A, and cyclin
B1, and the up-regulation of p21WAF1/CIP1 and p53 proteins
caused cell cycle arrest at the G2/M phase. There was an
apoptotic trigger which was an outcome of the activation of
caspases-3, -8, and -9, the loss of mitochondrial membrane
potential (19m), the release of cytochrome c into the cytosol
and changes in the expression of bcl-2 family proteins (Li
et al., 2005; Lee et al., 2012). Similar results were obtained by
yet another study, with elemene inducing a potential apoptotic
trigger (Lee et al., 2012). In the breast cancer MB-468 cells,
elemene in synergism with paclitaxel can down-regulate the cell
cycle protein cyclin-B1 expression and up-regulate the P27(kip1)
expression thereby leading to an inhibition of cell proliferation
(Cai et al., 2013). The human cisplatin-resistant ovarian cancer
cell lines A2780/CP and MCAS were chemosensitized by
elemene through the induction of apoptosis, mediated by a
mitochondria- and caspase-dependent (caspase-3/8/9) cell death
pathway. It upregulated the expression of pro-apoptotic Bax and
downregulated the anti-apoptotic Bcl-2 and Bcl-XL expressions
(Li et al., 2013c).
Therefore, the cancers of reproductive system are susceptible
to elemene via an apoptotic trigger as observed through the
outcomes of these experiments.
Endocrine System
Synergistic interaction of rapamycin and elemene influenced a
significant antiproliferative effect in FTC-133 thyroid cell line,
dependent on inhibiting the AKT feedback activation induced
by Rapamycin (Zhou et al., 2016). Inhibition of Akt activity by
Rapamycin has been related to induction of apoptosis (Dormond
et al., 2007). Therefore, the inhibition of Akt by Rapamycin in this
study could be correlated to an apoptotic trigger.
Urinary System
Elemene enhanced the activity of cisplatin by chemosensitization
against human bladder cancer 5637 and T-24 cells by elevating
expressions of caspase-3, -7, -8, -9, and -10 leading to apoptosis
through a caspase dependent mechanism (Li et al., 2013e).
Elemene downregulates the expression of survivin, Bcl-xL, Mta-
1 and induces apoptosis in human bladder cancer T24 cells in
a time and dose dependent manner (Chen et al., 2012). This
suggests that apoptosis is the rationale behind the observed
antineoplastic effects in cancers of urinary system.
SENSITIZATION OF MULTIDRUG
RESISTANT CANCER CELLS
Elemene increased the susceptibility of multidrug resistant cancer
cells toward the respective drugs in several cases. It increased
the sensitivity of MDR leukemia (K562/DNR) and gastric cancer
lines (SGC7901/ADR), thereby enhancing the cytotoxic activity
of P-gp substrates (DOX, DNR, and EPI). This was achieved by
downregulation of Akt phosphorylation and upregulation of the
E3 ubiquitin ligases, c-Cbl and Cbl-b (Zhang et al., 2013). In
combination with anti-neoplastic drugs (colchicine, vinblastine
and paclitaxel), elemene was reported to produce effective
cytotoxicity by blocking eﬄux portion of ABCB1 transporters
that are over-expressed in KB-C2 cells (Guo et al., 2014). In
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TABLE 1 | Anticancer effect of β-elemene against cancer cell lines of multiple origin.
S. no Cell line type Genes/proteins involved Mode of action Reference
Integumentary system
1. Melanoma cells (B16F10),
Melanoma mice (C57BL/6)
VEGF Antiangiogenesis Chen et al., 2011
Nervous system
2. Glioblastoma cell line (U87) MKK3 and MKK6 Cell cycle arrest G0/G1 phase Zhu et al., 2011b
3. Glioblastoma cell line (U87) Glia maturation factor β ERK1/2-Bcl-2/survivin pathway
leading to apoptosis
Zhu et al., 2014
4. Glioblastoma cell line (C6 and
U251)
p38 MAPK phosphorylation Cell-cycle arrest at the
G0/G1phase
Yao et al., 2008a,b
5. Brain tumor cell lines (A172,
CCF-STTG1, and U-87MG)
Caspase-3/7/10, Bax, Bcl-2, Bcl-XL,
and XIAP
Apoptosis Li et al., 2013a
6. Glioma cell lines (U251 and
A172)
Caspase 9/3/7 and survivin Apoptosis Zhang et al., 2012
7. Glioma cell lines (C6 and
SHG-44)
Apoptotic bodies Apoptosis Zhou et al., 2003
Respiratory system
8. NSCLC cell lines (H460 and
A549)
Caspase 3/7/9, Bcl-2, and cytochrome
C
Apoptosis Wang et al., 2005
9. NSCLC cell line (A549) Bax, p53, p21, PARP, and cyclin D1. Apoptosis
10. NSCLC cell lines (PC9 and
H1299)
p21 Apoptosis Zhao et al., 2011
11. NSCLC cell lines (H460 and
A549)
Bax, phospho-Bcl-2, Bcl-2, and XIAP. Apoptosis Li et al., 2009
12. NSCLC cell lines (PC9, H1299,
H1650, A549, H358 and
H1975)
ERK1/2- and AMPKα Apoptosis Zhao et al., 2015
13. NSCLC cell lines (p53 mutant
H23 cells and p53 null H358
cells)
Bcl-2, Bcl-XL, caspase-8/3 Apoptosis Zhao et al., 2007
14. Laryngeal cell line (HEp-2),
HEp-2 cell-transplanted
BALB/c nude mice
Caspase-3, eIF4E, eIF4G, bFGF and
VEGF
Apoptosis and angiogenesis Tao et al., 2006
Immune system
15. Leukemia cell line (HL-60) Caspase-8, c-FLIP Apoptosis Yu et al., 2011
16. Leukemia cell line (HL-60) COX-2, NF-kappaB, and PGE2 Apoptosis Zheng et al., 2009
17. Multiple Myeloma cell line
RPMI-8226
Caspase-3 and DR-4, bcl-2,
NF-kappaB, and p65
Apoptosis Chen et al., 2010
18. Acute promyelocytic leukemia
cell line (NB4)
Caspase-3 ROS, Apoptosis Yu, 2010
Digestive system
19. Hepatocellular carcinoma cell
lines (MHCC97H and Hep3B)
Fas/FasL Cell cycle arrest (G2/M) and
apoptosis
Dai et al., 2013
20. Gastric adenocarcinoma cell
line (SGC7901/ADM)
NF-kappaB Apoptosis Fu et al., 2013
Reproductive system
21. Prostate carcinoma cell line
(DU145 and PC-3)
Bcl-2, Activated PARP, caspase
3/7/9/10, and cytochrome c
Apoptosis Li et al., 2010a
22. Prostate carcinoma cell line
(DU145 and PC-3)
Caspases-3/7/9/10, Bcl-2, and Bcl-XL Apoptosis Li et al., 2010b
23. Cisplatin-sensitive human
ovarian cancer cell line (A2780)
CDK CDC2, cyclin A, cyclin B1,
p21WAF1/CIP1, p53, caspases 3/8/9
Cell cycle arrest at the G2/M
phase
Li et al., 2005; Lee et al.,
2012
24. Breast cancer cell line (MB-468) Cyclin-B1 expression and up-regulate
the p27
Cell cycle inhibition Cai et al., 2013
25. Cisplatin-resistant ovarian
cancer cell lines (A2780/CP
and MCAS)
Caspase-dependent cell death Apoptosis Li et al., 2013b
(Continued)
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TABLE 1 | Continued
S. no Cell line type Genes/proteins involved Mode of action Reference
Endocrine system
26. Thyroid cell line (FTC-133) AKT feedback activation Apoptosis Zhou et al., 2016
27. Bladder cancer cell line (5637 and T-24) Caspase 3/7/8/9/10 Apoptosis Li et al., 2013c
28. Bladder cancer cell line (T24) Bcl-xL, Mta-1, and survivin Apoptosis Chen et al., 2012
FIGURE 1 | Modes of cell death induced by β-elemene.
human BCA adriacin (Adr) – resistant MCF-7 cells (MCF-7/Adr)
and docetaxel (Doc) – resistant MCF-7 cells (MCF-7/Doc), PTEN
expression was significantly increased, whereas, Pgp expression
was decreased after treatment with elemene (Zhang et al., 2014).
SYNERGISTIC ANTICANCER EFFECTS
In lung cancer cell lines NSCLC H460 and A549, elemene
enhances cisplatin activity by increasing checkpoint kinase
(CHK2) and reducing CDC2 (Li et al., 2013d). Elemene along
with taxanes exhibited moderate synergistic antitumor activity
against ovarian (A2780/CP70) and prostate (PC-3) carcinomas
in vitro by increasing permeabilization of taxanes, micronuclear
formation, and binding with eﬄux pumps along with upregulated
expression of caspase-9 and p53 (Zou et al., 2013). It
sensitized ovarian carcinoma cells to cisplatin treatment by
down-regulating excision repair cross-complementation group-1
(ERCC-1) and XIAP through JNK pathway (Li et al., 2013a).
It potentiated the activity of endostar, a recombinant human
endostatin by inhibiting VEGF and MMP-2 leading to a decrease
in malignant ascites formation in H22 murine model (Jiang et al.,
2012).
CONTRADICTORY EFFECTS OF
ELEMENE
In human gastric cancer cell lines MGC803 and SGC7901,
protective autophagy was observed. According to the authors, the
combination of autophagy inhibitors such as 3-methyladenine
(3-MA) or chlorochine with elemene can induce apoptosis in
the cancer cells by causing an increase in antitumor effects of
elemene. Contraindicative to anticancer effects of elemene, when
treated alone, it induced protective effects on gastric cancer cells
(Liu et al., 2011). Similar observations of protective autophagy
were attained against the breast cancer Bcap37 and MBA-MD-
231 cells (Guan et al., 2014).
PROTECTIVE EFFECT AGAINST
NORMAL CELLS
Elemene exhibited low toxicity toward lung fibroblast
(CCD-19Lu) and human bronchial epithelial (NL20) normal
cell lines (Wang et al., 2005). In addition, elemene showed
less toxicity to ovarian epithelial cell line (IOSE-397) (Li
et al., 2005). It showed limited toxicity to macrophages and
Frontiers in Pharmacology | www.frontiersin.org 5 March 2017 | Volume 8 | Article 105
fphar-08-00105 March 7, 2017 Time: 14:25 # 6
Jiang et al. Cancer Cell Interaction of β-Elemene
reduced infiltration of the same in rabbit in vivo model (Zhong
et al., 2015).
FUTURE DIRECTIONS
Mechanistic approaches for the treatment of cancer, the modern
epidemic, using elemene had made considerable progress
over the recent past, resulting in decreased mortality rate.
Simultaneously, the disease susceptibility and drug responses for
elemene can be identified using specific molecular approaches.
The studies of this kind are still at their infancy. Although
available reports have cited elemene to be minimally toxic, this
effect can be elucidated better. Further, elemene-induced liver
injury has to be monitored. Adding to this, nano-formulations of
elemene can be derived to enhance the bioavailability and efficacy
of elemene, such that of nano-curcumin. This will eventually
lead to a better, more specific and efficient anticancer therapy,
devoid of side effects. Future studies that can elicit the exact
role of elemene in anticancer therapy and novel, specific drug
development methods are the need of the hour.
CONCLUSION
Elemene has been proven to possess anticancer activity. Decrease
in mitochondrial potential, upregulation of pro-apoptotic signals
and downregulation of anti-apoptotic signals are predominantly
observed in cancer cells treated with elemene. Therefore, from
the above results, it can be suggested that apoptosis has led to
the anticancer activity of elemene (Table 1 and Figure 1). This
is consistent with the molecular mechanism studied for other
preclinical and clinical drugs. The mini-review based on the
information presented, concludes that the β-elemene can be a
precious candidate for future anticancer medications.
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